The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

By S. Willingham, J. Volkmer, Andrew J. Gentles, D. Sahoo, Piero Dalerba, S. Mitra, Jian Wang, Humberto Contreras-Trujillo, Robin Martin, Justin D. Cohen and 34 more. Proceedings of the National Academy of Sciences of the United States of America, 2012

1,535 citations recorded by the source corpus.

Subfields: Immunology, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/a5d8e1615c86304da5d8b1e40515b1ac1938d6df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Beth Levine
2. J. Seita
3. Aldons J. Lusis
4. Irving L. Weissman
5. S. Pun
6. Douglas R. Green
7. Heather H Gustafson
8. Chayanon Ngambenjawong

In Physiology

1. Douglas R. Green
2. Beth Levine
3. S. Pun
4. Heather H Gustafson
5. Chayanon Ngambenjawong
6. I. Slaninová

In Surgery

1. Beth Levine
2. S. Pun
3. Heather H Gustafson
4. Chayanon Ngambenjawong

Citations in the corpus

• Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, positive): “2 Inhibition of CD47-SIRPα signaling—Successful development and maturation of tumors require effective evasion from such immune-surveillance activities [98].”
• Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response (2013, background): “We have demonstrated the therapeutic efficacy of anti-CD47 blocking mAbs against xenograft human cancers growing in immunodeficient mice, including cancers such as leukemia (5, 13), lymphoma (14), and multiple myeloma (15), solid tumors, including breast, colon, prostate, and bladder cancers, and sa”
• Macrophages in immunoregulation and therapeutics (2023, background): “Because of its association with SIRP on macrophages, CD47 is a poor prognostic marker in tumor cells, and this relationship helps tumor cells avoid phagocytic clearance by macrophages.(360,361) Inhibition of tumor growth mediated by macrophages has been achieved by blocking CD47.”
• CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis (2016, background): “We recently found that the key anti-phagocytic molecule, CD47, is paradoxically upregulated by a variety of cancers 5,7,15 .”